New inhaled compound aims to ease COPD breathing woes

NCT ID NCT06748079

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This early-stage trial is testing an experimental inhaled medication called TQC3721 in people with moderate to severe chronic obstructive pulmonary disease (COPD). The study aims to see how safe and tolerable the drug is, how it moves through the body, and what effects it has on lung function and symptoms. Participants will receive either the drug or a placebo, and some may also receive a combination with another inhaled medication. The results will help determine if this approach is worth further study as a potential COPD treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
TQC3721 inhalation powder (a target inhibitor) given alone or with glyberlam inhalation powder, compared against placebo
What this could lead to
If safe and well-tolerated, TQC3721 could become a new inhaled treatment to help control COPD symptoms and improve quality of life.
What could go wrong
This is an early Phase 1 trial focused on safety and dosing, not yet on effectiveness. The drug may not work as hoped or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, 610000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.